A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (18 to 45 Years) and Older Adults (greater than or equal to 60 Years).

Trial Profile

A Phase II, Double-Blind, Randomised, Controlled, Multi-Centre Study to Evaluate the Immunogenicity, Safety and Tolerability of Three Formulations of CSL412 in Adults (18 to 45 Years) and Older Adults (greater than or equal to 60 Years).

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2016

At a glance

  • Drugs CSL 412 (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors CSL
  • Most Recent Events

    • 24 Mar 2012 Planned patient number is 720 according to European Clinical Trials Database.
    • 23 Jan 2008 The expected completion date for this trial is now 1 Aug 2007.
    • 29 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top